Please login to the form below

Not currently logged in
Email:
Password:

FDA approves Novo Nordisk's diabetes drug

Novo Nordisk has received approval from the US FDA for its type 2 diabetes treatment, Victoza (liraglutide)

Danish pharmaceutical company, Novo Nordisk has announced it has been granted marketing authorisation from the US Food and Drug Administration (FDA) for its type 2 diabetes treatment, Victoza (liraglutide).

Victoza is approved for use in addition to diet and exercise to improve glycaemic control in adults with type 2 diabetes. It is the first once-daily human Glucagon-Like Peptide-1 (GLP-1) analogue developed for the treatment of type 2 diabetes.

"The US approval of Victoza represents a major advancement in the treatment of type 2 diabetes and is an important milestone for Novo Nordisk that follows the recent approval in Japan and the ongoing successful launch in Europe." said Lars Rebien Sørensen, president and CEO.

He continued: "We are convinced that Victoza will prove to be a valuable treatment option for people with type 2 diabetes in the US. The ability of Victoza to substantially improve glucose control with a low risk of hypoglycaemia creates an opportunity for more patients with type 2 diabetes to achieve their individual treatment goals."

Novo Nordisk plans to introduce Victoza to the US market within the next few weeks.

26th January 2010

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Fishawack Group of Companies

The Fishawack Group of Companies is one of the largest independent medical communications and medical marketing specialists, with teams in...

Latest intelligence

Women in science
The role of women in science and technology
Why the lack of female leaders in pharma and life sciences is a problem that still needs to be fixed...
Maria Dahl
China’s homecoming heroes fuel a biotech boom with rapid CAR-T advances
China secures a place at the forefront of innovative medicine...
Virtual Research Grants Submission and Approval Program
Impetus Digital summarizes how a client established an independent grant review committee and a virtual grant submission and approval program, without having to travel and meet in person....

Infographics